Connelly to lead Lilly’s U.S. unit, joins elite group

Share this article:
Eli Lilly yesterday named Deirdre Connelly president of Lilly USA.
The role gives Connelly direct responsibility for an affiliate that generated $7 billion in 2004 sales and has 6,600 employees.
In the process, Connelly joins an elite and growing band of female pharma execs, including Christine Poon, worldwide chairman of medicines and nutritionals at Johnson & Johnson, Karen Katen, vice chairman of Pfizer, Margaret McGlynn, president of U.S. Human Health Care at Merck, and Carrie Cox, president, global pharmaceutical business at Schering-Plough.
Connelly was promoted from the position of senior vice president for human resources, which she held only since last August. Succeeding her in that role is Anthony Murphy, formerly executive director for human resources.
She reports to John Lechleiter, executive vice president of pharmaceutical operations, who has had the additional task of leading U.S. operations since last July.
After joining Lilly's field force in 1984, Connelly held various positions, including leader of its U.S. women's health business unit and executive director of human resources for Lilly USA.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...